Skip to main content

RT @synovialjoints: IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO • Rapid improvement 4

Nov 12, 2022 6:00 pm
Social Author Name
Dr. Antoni Chan
Tweet Content
IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO • Rapid improvement 47.7 vs 21.4% • TNF naive 46.6 vs 22.9% • TNFIR 60 vs 11.8% • Wk 24 >50% ASDAS <2.1 • Improved MRI • Serious TEAE 0.4% Deodhar Abs0544 https://t.co/q9dbQP5oLD #ACR22 @RheumNow https://t.co/VCJgo56JrA
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×